1Ventura P,Rosa MC,Abbati G,et al.Hyperhomocysteinaemia in chronic liver diseases:Role of disease stage,vitamin status and methylenetetrahydrofolate reductase genetics[J].Liver Int,2005,25:49-56.
1Guba SC, Fink LM, Fonseca V. Hyperhomocysteinemia - an emerging and important risk factor for thromboembolic and cardiovascular disease.AM J Clin Pathol, 1996, 106(6):709-722
2Houseton PE, Rana S, Sekhsaria S, et al. Homocysteine in sickle cell disease: relationship to stroke. AM J Med, 1997, 103(3):192- 196
3Graham TM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA, 1997, 277(22):1775 - 1781
4Mayer EL, Jacobsen DM, Robinson K. Homocysteine and coronary atheroselcrosis. JACC, 1996, 27(3) :517 - 527
5Stead LM, Brosnan ME, Brosnan JT. Characterization of homocysteine metabolism in the rat liver. Biochem J, 2000, 350(3) :685 - 692
6Garcia-Tevijano ER, Berasain C, Rodriguez JA, et al. Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. Hypertension, 2001, 38(5): 1217 - 1221
5Malhi H ,Gores GJ. Cellular and molecular mechanisms of liver in- jury[J]. Gastroenterology,2008,134(6) :1641-1654.
6Mato JM, Lu SC. Homocysteine, the bad thiol[J]. Hepatology, 2005,41(7) :976-978.
7Oldenburg B,Van Tuyl BA, van der Griend R, et al. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia[J]. Dig Dis Sci, 2005,50(2): 235-240.
8Mahmood A, Needham J, Prosser J, et al. Prevalence of hyperho- mocysteinaemia,activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease[J]. Eur J Gastroen- terol Hepatol,2005,17(5):739-744.
9Ventura P, Rosa MC, Abbati G, et al. Hyperhomoeysteinaemia in chronic liver diseases: Role of disease stage, vtamin status and methlenetetradrofolate reduetase genetics[J]. Liver Int, 2005,25(1):49-56.
10HugleT,CernyA. Current therapy and new mol.ecular approaches to antiviral treatment and prevention of hepatitis C[J]. Rev Med Virol,2003,13(6) :361-371.
